Hepatocelular carcnoma (HCC) considered the common liver-cancer and the leading to death. The early diagnosises of HCC are the main benefits of HCC screening and α-1-acid glycoprotein (A1AG). The level of A1AG is marker for diagnosing HCC. Objective: Evaluation of the clinical utilites of AGP in HCC patients specially in attempt to find its role in diagnosing HCC in early stage. Methods: This study was performed on 85 patients recruited from Gastroenterology and Hepatology outpatient clinics and Internal Medicine Departments of Alahrar Zagazig Teaching Hospital, during the period from January2017 to January 2018 after obtaining a written consent from all subjects. Results: This study was performed on 85 patients. Group (I): (Healthy individuals) consists of 22 subjects included 10 males (45%) and 12 females (55%) with mean age 55.85±7.74 years. Group (II): (CLD-non HCC group) consists of 26 with cirrhosis included 19 males (73.1%) and 7females (26.9%) with mean age 58.4±4.7years. Group (III): (HCC group) consists of 37 HCC patients included 24 males (64.9%) and 13 females (35.1%) with mean age 60.45 ± 4.6 years. Conclusion: AGP is a sensitive and specific tumor marker for detection of HCC, especially for low AFP HCC. Combination between AGP and AFP increases the sensitivity and specificity of the diagnosis of HCC.